CTN :40950061
25 Jul, 2025
36.45 Crore
Tender For online tender for the rate contract for the supply of medicines to various hospitals of government of haryana for a period of two years for group a medicines - paracetamol tablet 500 mg, diclofenac + paracetamol tablet 50mg+325mg, framycetin cream 1%, 30 gm tube, normal saline (sodium chloride) injection 0.9% w/v, 500 ml bottle ( ffs technology), ringer lactate (solution ) for injection ( compound sodium lactate) 500 ml ffs bottle, amoxicillin + clavulanic acid injection 1.2 gm, 10 ml vial with diluents, dextrose 5 % w/v with sodium chloride 0.9% w/v for intravenous infusion 500 ml ffs bottle, plasma volume expander injection (each 100 ml contains polygeline, polypeptides of degaraded gelatin, cross linked via urea bridges 3.5 g (equivalent to 0.63 g of nitrogen) nacl ip 0.85 g, kcl ip 0.038 g cacl2 ip 0.070g water for injection ip q.s electrolytes in m.mol/litre, 500 ml ffs, levofloxacin tablet 500 mg, dextrose intravenous infusion ip 5 % w/v, 500 ml ffs bottle, aceclofenac tablet 100 mg, hydrocortisone ( sodium sucinate powder) injection 100 mg vial, with 2 ml distilled water for reconstitution, nitrofurantoin capsule 100 mg, clotrimazole pessaries 200 mg, ciprofloxacin injection 2mg/ml, 100 ml bottle for infusion ffs technology, multi electrolyte injection (isolyte p multiple electrolyte & dextrose injection type 1 ), 500 ml ffs bottle, ondansetron injection 2mg/ml, 2ml ampoule, acetylsalicylic acid tablet 75 mg gastro-resistant (enteric coated/ delayed release), paracetamol infusion 100 mg/10 ml, 100 ml bottle ffs technology, biphasic isophane injection 40 i.u/ml, (30/70), 10 ml vial, multi ext-red-selected">vitamin infusion 10 ml:
each ml contains
ext-r
ed-s
el
ect
ed">vitamin a (as
ext-r
ed-s
el
ect
ed">vitamin a conc
entrat
e oily form) lp 1100 lu, chol
ecalcif
erol lp 100 lu, tocoph
eryl ac
etat
e lp 0.5mg, nicotinamid
e lp 10mg, riboflavin sodium phosphat
e lp 1.4mg, pyridoxin
e hydrochlorid
e lp 1.65mg, thiamin
e hydrochlorid
e lp 5.0mg, ascorbic acid ip 50.0mg, l-cyst
ein
e hydrochlorid
e usp 0.2mg, b
enzyl alcohol (as pr
es
ervativ
e) lp 1.0% v/v, wat
er for inj
ections lp q.s, h
epatitis b immunoglobulin inj
ection 100 iu, 1 ml vial, d
extros
e intrav
enus infusion ip 10% w/v, 500 ml ffs bottl
e, c
efotaxim
e inj
ection 500 mg 5 ml vial with dilu
ent, lignocain
e inj
ection 2%, 30 ml vial, f
errous (iron sucros
e) inj
ection 20 mg/ml, tramadol hydrochlorid
e capsul
e 100 mg, d
extros
e intrav
enous infusion ip 25% w/v, 100 ml ffs bottl
e, lignocain
e hydrochlorid
e and adr
enalin
e bitartarat
e inj
ection 20mg/ml and 0.01mg/ml adr
enalin
e, 30 ml vial, ph
enytoin (sodium) inj
ection 100mg, 2ml amp., c
eftriaxon
e inj
ection 250 mg 2 ml vial with dilu
ent, m
ethyl pr
ednisolon
e inj
ection 1gm, 1 gm vial with dilu
ent, ampicillin sodium inj
ection 500mg 2 ml vial with dilu
ent, normal salin
e inj
ection 3%, adr
enalin
e inj
ection 1 mg/ml, 1:1000, 1 ml amp, amoxicillin + clavulanic acid inj
ection 250 mg +50 mg, vial with dilu
ents, isofluran
e inhalation 100 ml vial, magn
esium sulphat
e inj
ection 1 gm /2ml (50%w/v), 2 ml ampoul
e, thiamin
e inj
ection 100 mg/ml, 2 ml vial, parac
etamol inj
ection 150 mg/ml, 2 ml amp., k
etamin
e (as hydrochlorid
e) inj
ection 50 mg /ml,10 ml vial, propofol inj
ection 1% vial (10 mg/ml, 10 ml vial), isoxsuprin
e inj
ection 5 mg/ ml, 2ml ampoul
e, ad
enosin
e inj
ection 3 mg/ ml, 1 ml ampoul
e, magn
esium sulphat
e inj
ection 2.5 gm /5ml(50%w/v), 5 ml ampoul
e, potassium chlorid
e (solution) inj
ectabl
e 15% (150mg/ml), 10 ml amp., hydroxycobalamin inj
ection 1 mg/ ml, diaz
epam inj
ection 5 mg/ml, 2 ml ampoul
e, aminophyllin
e inj
ection 25 mg/ ml, 10 ml ampoul
e, dobutamin
e inj
ection 250mg/5ml, m
ethyl
ergom
etrin
e inj
ection 200 mcg in 1 ml ampoul
e, toras
emid
e tabl
et 10 mg, t
etanus toxoid inj
ection 0.5 ml ampoul
e,
etophyllin
e + th
eophyllin
e inj
ection 169.4 mg + 50.6 mg/2 ml ampoul
e, ciprofloxacin ophthalmic ointm
ent 0.3% 5 gm tub
e, alb
endazol
e ch
ewabl
e tabl
ets 400 mg(th
e ch
ewabl
e tabl
ets shall also comply with th
e t
est for disint
egration and dissolution as p
er monograph giv
en in int
ernational pharmacop
eia as p
er r
equir
em
ent of goi)